Work

Abstract B199: Targeting the tumor microenvironment with first-in-class Semaphorin4D MAb for combination immunotherapy

Year: 2018

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-17-b199

Authors: Elizabeth E. Evans, Holm Bussler, Crystal Mallow, Christine Reilly, Sebold Torno, Maria Scrivens, Cathie Foster, Alan Howell, Leslie Balch, John E. Leonard, Terrence L. Fisher, Clint Allen, Paul Clavijo, Siwen Hu-Lieskovan, Antoni Ribas, Ernest S. Smith, Maurice Zauderer

Institutions: Vaccinex (United States), National Institutes of Health, National Institute on Deafness and Other Communication Disorders, University of California, Los Angeles

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2885815839

Cites:

Cited by:

Related to: 10